ArticleAntimicrobial agents and chemotherapy2020
CRISPR-Cas9-Mediated Carbapenemase Gene and Plasmid Curing in Carbapenem-Resistant
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- CRISPR-Cas systems in combating antimicrobial resistance: which system to choose? A systematic review.World journal of microbiology & biotechnology · 2025Pooled it
- Plasmid encodedBiofilm · 2026Article
- Phage and CRISPR based precision antimicrobials: a dual strategy against multidrug-resistant bacteria.Molecular biology reports · 2026Review
- Distinct and shared impacts of virulence plasmids on the phenotype and transcriptome in convergent carbapenem-resistant and hypervirulentMicrobiology spectrum · 2026Article
- OmpK35/36 modulate the virulence of hypervirulent Klebsiella pneumoniae by regulating capsular polysaccharide export.BMC microbiology · 2026Article
- Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021.Emerging infectious diseases · 2026Review
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Emergence of hypervirulent Klebsiella pneumoniae ST111 with a novel virulence plasmid causing pyogenic liver abscess.BMC microbiology · 2026Article
- Genetic basis of cefiderocol resistance inMicrobiology spectrum · 2026Article
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Functional characterization of a type I-F1 CRISPR-cas system from the clinical isolate Shewanella xiamenensis Sh95 reveals constitutive activity and plasmid-curing capability.Scientific reports · 2026Article
- CRISPR-Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance.Pharmaceutics · 2026Review
- CRISPR-Cas based plasmid design for multidrug-resistant Klebsiella pneumoniae isolates.FEMS microbiology letters · 2026Article
- Article
- OmpK35/36 absence does not confer carbapenem-resistance alone nor ceftazidime-avibactam resistance with oneFrontiers in cellular and infection microbiology · 2026Article
- Evolution and high transferability of an IncN/FII plasmid harboring blaBMC microbiology · 2025Article
- A critical role of copper homeostasis in the virulence of Klebsiella pneumoniae.Communications biology · 2025Article
- Emergence ofbioRxiv : the preprint server for biology · 2025Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Combating plasmid-mediated carbapenem resistance is essential to control and prevent the dissemination of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.